Noradrenergic Drug Market Size

  • Report ID: 3817
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Noradrenergic Drug Market Size

Noradrenergic Drug Market size was over USD 17.03 billion in 2024 and is projected to reach USD 24.7 billion by 2037, witnessing around 2.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of noradrenergic drug is assessed at USD 17.83 billion.
 

The growth of the market can be attributed to the growing prevalence of mental disorders across the globe. Norepinephrine drugs are used to treat the symptoms of different mental health issues. These drugs control the body's levels of neurotransmitters and increase alertness and concentration. According to estimates, more than 7% of Indians suffer from some mental disorder.

 In addition to these, factors that are believed to fuel the market growth of noradrenergic drugs include the rising lifestyle disorders. For instance, high-stress conditions can lead to several disorders such as anxiety, depression, blood pressure, and cardiovascular diseases. Noradrenaline drugs can be utilized to treat anxiety and depression. Further, mood and attentiveness are all impacted by norepinephrine. Additionally, the growing prevalence of Attention-deficit/hyperactivity disorder (ADHD) is predicted to present the potential for market expansion over the projected period.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3817
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of noradrenergic drug is assessed at USD 17.83 billion.

The noradrenergic drug market size was over USD 17.03 billion in 2024 and is projected to reach USD 24.7 billion by 2037, witnessing around 2.9% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of autism, and surging incidences of hypertension will boost the market growth.

Asia Pacific industry is estimated to account for largest revenue share of 37% by 2037, attributed to increasing popularity of antidepressants among the adult population in the region.

The major players in the market are Baxter International, Inc., Eli Lilly and Company, Novartis AG, Bayer AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample